Beth H. Lowenthal

Articles by Beth H. Lowenthal

TPS 105 ALISertib in Combination With Endocrine Therapy in Patients With Hormone Receptor-Positive, HER2-Negative Recurrent or Metastatic Breast Cancer: the Phase 2 ALISCA-Breast1 Study

ByPooja Advani, MBBS, MD,Sofia Braga,Adam M. Brufsky, MD, PhD,Karthik V. Giridhar,Erica L. Mayer, MD, MPH,Kelly E. McCann,Ruth M. O’Regan,Cristina Saura,Seth A. Wander,Georg F. Bischof,Beth H. Lowenthal,Judith D. Bebchuk,Lisa D. Eli,Brian G. Barnett,Joyce A. O’Shaughnessy,Tufia C. Haddad

April 11th 2025

Latest Updated Articles

Trending on CancerNetwork

BNT113/Pembrolizumab Misses PFS End Point in HPV16+ Head and Neck Cancer

RYZ101 Improves Progression-Free Survival in Previously Treated GEP-NETs

Why CAR T-Cell Therapy Before Bispecifics May Be the Ideal Multiple Myeloma Sequence

Teclistamab Vs Talquetamab After Relapse on CAR T-Cell Therapy in Multiple Myeloma

How Might IMiD Holding Therapy Impact Outcomes in R/R Multiple Myeloma?